Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM EBIT Multiple | 28,0x - 31,0x | 29,5x |
Selected Fwd EBIT Multiple | 23,3x - 25,8x | 24,6x |
Fair Value | ₩14.188 - ₩16.009 | ₩15.099 |
Upside | 11,2% - 25,5% | 18,3% |
Benchmarks | Ticker | Full Ticker |
JW Lifescience Corporation | A234080 | KOSE:A234080 |
Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
Yuyu Pharma, Inc. | A000220 | KOSE:A000220 |
Whan In Pharm Co.,Ltd. | A016580 | KOSE:A016580 |
KUKJEON PHARMACEUTICAL Co., Ltd | A307750 | KOSDAQ:A307750 |
Ilyang Pharmaceutical Co.,Ltd | A007570 | KOSE:A007570 |
- | - | - |
Select LTM EBIT Multiple | |||||||
Benchmark Companies | |||||||
A234080 | A011040 | A000220 | A016580 | A307750 | A007570 | ||
KOSE:A234080 | KOSDAQ:A011040 | KOSE:A000220 | KOSE:A016580 | KOSDAQ:A307750 | KOSE:A007570 | ||
Historical EBIT Growth | |||||||
5Y CAGR | 3.8% | -36.1% | 9.3% | -3.9% | NM- | -19.5% | |
3Y CAGR | 8.1% | -45.0% | 118.9% | -11.8% | -60.8% | -10.2% | |
Latest Twelve Months | 19.2% | 122.8% | 508.9% | -40.7% | -120.7% | -32.8% | |
Historical EBIT Profit Margin | |||||||
5 Year Average Margin | 16.6% | 2.5% | 3.3% | 14.4% | 3.7% | 6.6% | |
Prior Fiscal Year | 14.9% | -15.3% | -0.5% | 13.1% | 5.3% | 6.1% | |
Latest Fiscal Year | 16.1% | 1.4% | 9.4% | 8.3% | 0.3% | 4.1% | |
Latest Twelve Months | 15.0% | 2.5% | 8.9% | 7.1% | -0.8% | 4.1% | |
Current Trading Multiples | |||||||
EV / LTM Revenue | 0.92x | 0.48x | 0.50x | 0.35x | 1.44x | 1.09x | |
EV / LTM EBITDA | 4.3x | 9.5x | 3.8x | 3.3x | 47.0x | 14.1x | |
EV / LTM EBIT | 6.1x | 18.9x | 5.7x | 4.9x | -173.8x | 26.6x | |
Low | Mid | High | |||||
Benchmark EV / LTM EBIT | -173.8x | 5.7x | 18.9x | ||||
Historical EV / LTM EBIT | -107.0x | 20.3x | 41.4x | ||||
Selected EV / LTM EBIT | 28.0x | 29.5x | 31.0x | ||||
(x) LTM EBIT | 11,000 | 11,000 | 11,000 | ||||
(=) Implied Enterprise Value | 308,527 | 324,765 | 341,003 | ||||
(-) Non-shareholder Claims * | (56,076) | (56,076) | (56,076) | ||||
(=) Equity Value | 252,451 | 268,689 | 284,927 | ||||
(/) Shares Outstanding | 18.0 | 18.0 | 18.0 | ||||
Implied Value Range | 14,014.61 | 14,916.06 | 15,817.51 | ||||
FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
Implied Value Range (Trading Cur) | 14,014.61 | 14,916.06 | 15,817.51 | 12,760.00 | |||
Upside / (Downside) | 9.8% | 16.9% | 24.0% |
Equity Waterfall | |||||||
Benchmark Companies | |||||||
(in millions) | A234080 | A011040 | A000220 | A016580 | A307750 | A007570 | |
Enterprise Value | 222,123 | 93,170 | 66,984 | 89,217 | 194,816 | 285,927 | |
(+) Cash & Short Term Investments | 26,465 | 32,582 | 45,546 | 54,601 | 38,582 | 12,790 | |
(+) Investments & Other | 2,062 | 68,323 | 8,827 | 31,625 | 5,185 | 43,510 | |
(-) Debt | (65,299) | (36,205) | (34,084) | (788) | (57,868) | (107,681) | |
(-) Other Liabilities | 0 | (261) | (10,240) | 0 | 161 | (3,582) | |
(-) Preferred Stock | 0 | 0 | (2,592) | 0 | 0 | (1,113) | |
(-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
Value of Common Equity | 185,350 | 157,609 | 74,440 | 174,655 | 180,877 | 229,851 | |
(/) Shares Outstanding | 15.5 | 26.9 | 16.2 | 15.3 | 50.0 | 18.0 | |
Implied Stock Price | 11,970.00 | 5,850.00 | 4,600.00 | 11,440.00 | 3,620.00 | 12,760.00 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
Implied Stock Price (Trading Cur) | 11,970.00 | 5,850.00 | 4,600.00 | 11,440.00 | 3,620.00 | 12,760.00 | |
Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |